China-based Impact Therapeutics has commenced its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX), seeking to raise up to HKD 901 million (USD 115 million). The offering, scheduled to list on 13 May 2026, is jointly sponsored by Goldman Sachs and CICC. The company has secured a strong cornerstone investor lineup, including a USD 10 million investment from existing shareholder Tencent, USD 5 million from Lilly Asia Ventures, and USD 5 million from Foresight Funds.

Founded in 2009, Impact is focused on developing precision oncology drugs based on the synthetic lethality mechanism. It is one of only three companies globally with both a commercialised PARP1/2 inhibitor and a next-generation selective PARP1 inhibitor in clinical development. Its lead product, senaparib, is approved in China for the first-line maintenance treatment of ovarian cancer and was included in the National Reimbursement Drug List (NRDL) in December 2025. Its commercialisation is handled by Huadong Medicine. The company's pipeline includes four clinical-stage and seven preclinical candidates targeting synthetic lethality pathways, as well as a bispecific antibody-drug conjugate (ADC) platform.

PharmCube's MedAlpha® database shows that Impact has raised USD 180 in 7 previous funding rounds, with Lilly Asia Ventures participating in most events. Click here to request a free trial for MedAlpha®.